Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors
Recorded on Tuesday, August 24, 2021
Healthcare providers can receive CME credit for important CLL topics with speakers Drs. Matthew Davids and Susan O’Brien.
Novel targeted therapies such as BTK inhibitors are bringing hope to (chronic lymphocytic leukemia) CLL patients. Yet tailored therapies can make determining the right options complex. Join expert hematologists and oncologists to review recommended therapy selection strategies, discuss key treatment combinations and evaluate BTK inhibitors for managing relapsed or refractory disease. You can earn AMA PRA Category 1 Credit™.
Emerging Combinations for Newly Diagnosed CLL
High‐Risk Relapsed/Refractory (R/R) CLL